Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 9Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × sagopilone × Clear all
NCT00299390 2015-12-31

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Bayer

Phase 2 Terminated
10 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00496379 2013-03-14

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡